Cited 0 times in Scipus Cited Count

Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy

DC Field Value Language
dc.contributor.authorRoh, TH-
dc.contributor.authorMoon, JH-
dc.contributor.authorPark, HH-
dc.contributor.authorKim, EH-
dc.contributor.authorHong, CK-
dc.contributor.authorKim, SH-
dc.contributor.authorKang, SG-
dc.contributor.authorChang, JH-
dc.date.accessioned2022-11-23T07:32:49Z-
dc.date.available2022-11-23T07:32:49Z-
dc.date.issued2020-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/22831-
dc.description.abstractThis study was conducted to assess whether levetiracetam (LEV) affects the survival of patients with glioblastoma (GBM) treated with concurrent temozolomide (TMZ) chemotherapy. To this end, from 2004 to 2016, 322 patients with surgically resected and pathologically confirmed isocitrate dehydrogenase (IDH)-wildtype GBM who received TMZ-based chemoradiotherapy were analysed. The patients were divided into two groups based on whether LEV was used as an anticonvulsant both at the time of surgery and the first visit thereafter. The median overall survival (OS) and progression-free survival (PFS) were compared between the groups. The OS was 21.1 and 17.5 months in the LEV (+) and LEV (-) groups, respectively (P = 0.003); the corresponding PFS was 12.3 and 11.2 months (P = 0.017). The other prognostic factors included age, extent of resection, O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, and Karnofsky Performance Status (KPS) score. The multivariate analysis showed age (hazard ratio [HR], 1.02; P < 0.001), postoperative KPS score (HR 0.99; P = 0.002), complete tumour resection (HR 0.52; P < 0.001), MGMT promoter methylation (HR 0.75; P < 0.001), and LEV use (HR 0.72; P = 0.011) were significantly associated with OS. In conclusion, LEV use was associated with prolonged survival in patients with GBM treated with concurrent TMZ chemoradiotherapy.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHChemoradiotherapy-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHGlioblastoma-
dc.subject.MESHHumans-
dc.subject.MESHLevetiracetam-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTemozolomide-
dc.titleAssociation between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy-
dc.typeArticle-
dc.identifier.pmid32612203-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330022-
dc.subject.keywordCNS cancer-
dc.subject.keywordDisease-free survival-
dc.contributor.affiliatedAuthorRoh, TH-
dc.type.localJournal Papers-
dc.identifier.doi10.1038/s41598-020-67697-w-
dc.citation.titleScientific reports-
dc.citation.volume10-
dc.citation.number1-
dc.citation.date2020-
dc.citation.startPage10783-
dc.citation.endPage10783-
dc.identifier.bibliographicCitationScientific reports, 10(1). : 10783-10783, 2020-
dc.identifier.eissn2045-2322-
dc.relation.journalidJ020452322-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Neurosurgery
Files in This Item:
32612203.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse